Date: 2014-12-02
Type of information: Company acquisition
Acquired company: Ariosa Diagnostics (USA - CA)
Acquiring company: Roche (Switzerland)
Amount: undisclosed
Terms: * On December 2, 2014, Roche announced the acquisition of Ariosa Diagnostics, a privately-held company based in San Jose, California, USA. Ariosa is a molecular diagnostics testing service provider that provides a highly targeted, nd accurate non-invasive prenatal testing (NIPT) service through their CLIA laboratory using cell-free DNA (cfDNA) technology. The closing of the transaction is expected to take place in December, 2014.
Details: Ariosa’s proprietary Harmony™ Prenatal Test is a blood test that is performed as early as 10 weeks into pregnancy. By evaluating fetal cfDNA found in maternal blood, the test is designed to assess the risk of Down syndrome and other genetic abnormalities. Specifically, the test assesses the risk of trisomies 13, 18, and 21, which are indicative of an extra chromosome in the fetus that can lead to severe genetic conditions. The test has been validated to CLIA requirements by a robust clinical data set and supported by clinical studies in more than 22,000 women of all ages and risk categories.
Related: Diagnostic
